Lindsey Shapiro, PhD,  science writer—

Some people with ANCA-associated vasculitis (AAV) have elevated biomarkers suggesting activation of the immune system’s complement cascade, which is known to contribute to AAV, even when they’re in disease remission, a study showed. While these biomarkers did not appear to be associated with an increased risk of future disease…

The selective immunosuppressive medication abatacept failed to significantly prevent treatment failure relative to a placebo in people with relapsing, non-severe granulomatosis with polyangiitis (GPA) taking part in a Phase 3 clinical trial, new data show. In addition to failing to meet this main goal of the study — called…

Immune neutrophils and the weblike structures they release to trap and kill microbes — called neutrophil extracellular traps, or NETs — are key players in driving kidney damage in ANCA-associated vasculitis (AAV) and other diseases, a review study found. This points to neutrophils and NETs as potential targets for…

The U.S. Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare form of ANCA-associated vasculitis (AAV). Developed by AstraZeneca, Fasenra was already approved in more than 80 countries, including the U.S., as an add-on treatment…

Fasenra (benralizumab), which is approved for a rare type of asthma, and Nucala (mepolizumab) were similarly effective at inducing remission in eosinophilic granulomatosis with polyangiitis (EGPA), but more people on Fasenra were able to stop using oral corticosteroids (OCS), with fewer monthly injections. That’s according to final published…

End-stage kidney disease (ESKD) that required dialysis or a kidney transplant was associated with an elevated risk of death among people with ANCA-associated vasculitis (AAV), compared to patients who didn’t develop the complication, research indicates. A kidney transplant was associated with better prognosis compared to dialysis. On kidney biopsies,…

A worse physical health-related quality of life (HRQoL) at diagnosis was associated with a higher mortality risk among a group of ANCA-associated vasculitis (AAV) patients in Korea, according to a new report. This risk was particularly noted in people with the AAV types microscopic polyangiitis, or MPA, and granulomatosis…

A first patient has been dosed in a Phase 2 clinical trial testing lixudebart, Alentis Therapeutics‘ investigational antibody therapy, in ANCA-associated vasculitis (AAV) patients with rapidly progressing glomerulonephritis (RPGN), a serious kidney disease. The study, RENAL-F02 (NCT06047171), currently is recruiting up to 60 adults with AAV…

Blood levels of ANCAs — the disease-causing antibodies that give ANCA-associated vasculitis (AAV) its name — can be used to help distinguish AAV from other conditions in which ANCAs might also be present, a study showed. Higher levels of the antibodies at diagnosis also were significantly tied to greater…

ANCA-associated vasculitis (AAV) patients with kidney disease have significantly more activity among six genes associated with forming neutrophil extracellular traps (NETs), a type of antimicrobial web produced by immune neutrophil cells, a study shows. The activity levels of these genes increases with kidney function decline and is tied to…